2024
Phase 2 open label, multicenter study evaluating CRG-022, a CD22-directed autologous CAR T-cell therapy, in patients (pts) with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) after CD19-directed CAR T-cell therapy.
Ghobadi A, Jacobson C, McGuirk J, Shah N, Rossi J, Buchholz T, Bachier-Rodriguez L, Baird J, Diefenbach C, Farooq U, Hernandez-Ilizaliturri F, Isufi I, Patel K, Neelapu S, Sauter C, Spiegel J, Tees M, Timmerman J, Laport G, Frank M. Phase 2 open label, multicenter study evaluating CRG-022, a CD22-directed autologous CAR T-cell therapy, in patients (pts) with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) after CD19-directed CAR T-cell therapy. Journal Of Clinical Oncology 2024, 42: tps7085-tps7085. DOI: 10.1200/jco.2024.42.16_suppl.tps7085.Peer-Reviewed Original ResearchCAR-T cell therapyCD19-directed CAR T-cell therapyDiffuse large B-cell lymphomaT-cell therapyB-cell lymphomaCytokine release syndromeOverall response rateLarge B-cell lymphomaR/R LBCLT cells/kgAdverse eventsAutologous CAR-T cell therapyHigh grade B-cell lymphomaBispecific T-cell engager antibodiesPrimary mediastinal B-cell lymphomaPhase 2 open-labelRecommended phase 2 doseAllogeneic stem cell transplantationGrade B-cell lymphomaMediastinal B-cell lymphomaInduce long-term remissionT-cell engager antibodiesResponse ratePhase 2 doseComplete response rate
2023
Prediction Modeling of CAR-T Cell Therapy for Diffuse Large B-Cell Lymphoma Using Artificial Neural Networks on Tumor Vascular Phenotype
Verma A, Liburd S, Tobias Z, Isufi I, Pober J, Xu M. Prediction Modeling of CAR-T Cell Therapy for Diffuse Large B-Cell Lymphoma Using Artificial Neural Networks on Tumor Vascular Phenotype. Blood 2023, 142: 2075. DOI: 10.1182/blood-2023-184963.Peer-Reviewed Original ResearchDiffuse large B-cell lymphomaPre-treatment biopsiesVenular endothelial cellsLarge B-cell lymphomaMemory T cellsHigh endothelial venulesT cellsB-cell lymphomaVCAM-1E-selectinICAM-1Endothelial cellsChimeric antigen receptor T-cell therapyL-selectinPre-treatment tumor biopsiesEffector memory T cellsCentral memory T cellsCAR T-cell therapyCell therapyHEV endothelial cellsInflamed lymph nodesT-cell infiltratesT cell exhaustionT-cell therapyT-cell homing
2020
Cost-effectiveness of polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma
Patel KK, Isufi I, Kothari S, Foss F, Huntington S. Cost-effectiveness of polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. Leukemia & Lymphoma 2020, 61: 3387-3394. PMID: 32835553, DOI: 10.1080/10428194.2020.1808208.Peer-Reviewed Original ResearchConceptsIncremental cost-effectiveness ratioLarge B-cell lymphomaB-cell lymphomaPola-BRR DLBCLRefractory diffuse large B-cell lymphomaLonger progression-free survivalRecent phase II trialDiffuse large B-cell lymphomaProgression-free survivalTransplant-ineligible patientsPhase II trialUS payer perspectiveCost-effectiveness ratioII trialOverall survivalTreatment strategiesPayer perspectiveLifetime horizonIncremental effectivenessIncremental costPolatuzumabRituximabLymphomaDLBCL